Your own sentinel for estimating DNA damage

Reading the breaks
in every strand.

POLEX™ is our DNA break detection platform — powered by nanopore sequencing and AI. We map single- and double-strand breaks at base resolution, turning raw ionic signal into genome-wide damage landscapes in hours, not weeks.

Get in touch →
About · Mission

We build at the interface of biology and engineering.

Where single-molecule genomics, deep bioinformatics, and machine learning converge to make DNA damage visible at the resolution disease actually happens.

◎ Mission

To turn invisible DNA damage into actionable signal — giving every patient, every therapy, and every cell a clear readout of genome integrity.

✦ Vision

A future in which DNA damage is no longer the silent driver of disease, but a measurable, interpretable, and treatable signal at the heart of every diagnosis and every cure.

⚛ Approach

Long-read nanopore sequencing + custom bioinformatics + deep learning, productised as POLEX™ — the first platform to map double-strand breaks at single-base resolution, genome-wide.

Application areas

DNA break detection, across the spectrum of disease.

POLEX maps chromosomal fragility in every condition where DNA damage matters — pick a domain to see the disease atlas.

50 tumor types

Cancer

BRCA1/2 breast, glioblastoma, PDAC, MSI-H colorectal, HRD ovarian, leukemias, pediatric sarcomas. Sorted by prognosis, filterable by category.

Explore cancer atlas →
15 disorders

Neurodegeneration

Ataxia-telangiectasia, Huntington, ALS, Alzheimer's, Parkinson's, Friedreich's ataxia. When neurons can't keep up with a lifetime of DNA damage.

Explore neuro atlas →
15 syndromes

Premature ageing

Hutchinson-Gilford, Werner, Cockayne, xeroderma pigmentosum, Bloom. Repair machinery failing at the source.

Explore progeroid atlas →
15 conditions

Gene therapy & immunity

SCID (RAG / Artemis / DNA-PKcs), Fanconi anaemia, Nijmegen, hyper-IgM. V(D)J breaks that don’t resolve, and where gene therapy is changing outcomes.

Explore immuno atlas →
POLEX™ · Proprietary Platform

Signal to break call, end-to-end.

The POLEX platform pairs nanopore sequencing with purpose-built AI to resolve DNA breaks at base resolution. See the full pipeline, the neural network, and the zoom from cell to base pair.

Explore the POLEX platform →
PIPELINE

Nanopore → calls

Signal capture, transformer basecalling, CNN break detection, genome mapping, interactive report.

AI MODELS

Three core models

NeuroBase for basecalling, BreakSeer for break classification, ContextNet for genomic context.

OUTPUT

Base-resolution break map

Single-strand breaks (SSB), double-strand breaks (DSB), complex lesions, with motif context and confidence scores.

Sample preview

Break burden across 10 tissue samples

Representative POLEX output. Each bar is one patient sample; colours split single-strand, double-strand, and complex lesions. Animates into view when scrolled to.

SSB DSB Complex
42S01
28S02
51S03
24S04
45S05
37S06
55S07
32S08
27S09
49S10
Research · Applications

Where our platform goes to work.

DNA breaks sit at the heart of cancer, ageing, neurodegeneration, and gene therapy.

01 / APPLICATION

Genotoxicity Screening

Quantify DNA break burden after compound exposure — sensitive, dose-responsive, genome-wide.

02 / APPLICATION

Gene-editing QC

Profile on- and off-target breaks from CRISPR, base editors, and prime editors at single-read resolution.

03 / APPLICATION

Oncology & DDR

Track damage, repair kinetics, and mutational signatures across tumor models and patient samples.

04 / SERVICE

End-to-end Sequencing

Send samples — receive annotated break maps, hotspot calls, and an interactive report.

05 / SERVICE

Research Collaborations

Joint programs with academic and industry partners on novel indications and assay development.

Team · Leadership

The people building In2Cell.

Click any card to read the full biography. We’re actively recruiting for CEO and CDO — if you’re interested, get in touch.

Actively recruiting
Chief Executive Officer (CEO)

Open role

Looking for an experienced commercial leader to drive partnerships, fundraising and clinical rollout.

View bio →
Founder · Chief Technology Officer (CTO)

Dr. Santosh Kumar

Building the POLEX platform end-to-end — from nanopore signal to clinical report.

Actively recruiting
Chief Financial Officer (CFO)

Open role

Owning financial planning, fundraising, and grant accounting as we move from seed to clinical pilots.

View bio →
Co-founder · Scientific Advisor (SA)

Prof. Fumiko Esashi

DNA repair biology — bringing decades of mechanistic insight to POLEX’s break-calling models.

View bio →
Scientific Advisor (SA)

Dr. Mike Boemo

DNA replication and nanopore signal analysis — developer of DNAscent at the University of Cambridge.

View bio →
Co-founder & Scientific Advisor (SA)

Dr. Shivani Patel

Oncology — bridging clinical practice with platform development to make break detection actionable for clinicians.

Actively recruiting
Chief Data Officer (CDO)

Open role

Leading the ML, model-ops and clinical-data infrastructure for the POLEX platform.

Actively recruiting
Quality Assurance Manager

Open role

Building the quality system — SOPs, validation, document control and audit-readiness for clinical-grade work.

Research Scientists & Associates

Actively recruiting
Research Scientist

Open role

Wet-lab scientist to build and validate nanopore break-detection assays. PhD + 3–5 yr post-doc preferred.

Actively recruiting
Research Associate

Open role

Bench scientist to run samples, build SOPs and support the assay team. MSc or BSc with lab experience.

Publications · News

Latest from the lab.

Event

In2Cell selected for CTA 5.0 — Cancer Tech Accelerator.

In2Cell Biosciences was selected to attend the fifth cohort of the Cancer Tech Accelerator (CTA 5.0) Bootcamp — chosen from 89 applicant teams spanning 12 countries across four continents. The one-week intensive brings together early-stage cancer-tech founders for commercialisation training, investor-readiness, and clinical-translation guidance. Day four was hosted at Triton Square, Cancer Research UK’s London headquarters, with sessions on European biotech investor activity and a founder Q&A panel.

CTA 5.0 cohort meeting — In2Cell with the Cancer Tech Accelerator team
In2Cell
CTA 5.0 investor activity session at Triton Square CTA 5.0 founder Q&A panel
13–17 April 2026 · Cancer Tech AcceleratorCTA 5.0 cohort
For Investors

Pre-seed round opening.

We’ve raised £140k in non-dilutive grant funding to date — from BBSRC and the Guy Newton Translational Award via the Sir William Dunn School of Pathology, University of Oxford. We’re now opening a pre-seed round to scale the wet lab, build out the AI and clinical team, and validate POLEX across our first oncology and neurodegeneration cohorts.

Request deck → IR contact
£140kGrant funding raised
Pre-seedRound opening
4 +6 hiringTeam
2Grants secured
Funding · Affiliations

Supported by.

Our work is built on the foundation of UK research councils and translation partners.

University of Oxford MRC — Medical Research Council BBSRC — Biotechnology and Biological Sciences Research Council Cancer Research Horizons
Collaboration

In collaboration with.

Umbizo umbizo.co.uk → HQ Science hq-science.com →
Contact · Careers

Let's work together.

Send a message

We read everything that comes in and reply within a few business days.

✉

Email

shashisantosh2007@gmail.com
☎

Phone

◎

Office

In2Cell Biosciences
27 Little Hay Road
Oxford, OX4 3EG

→ Careers

Hiring across science, engineering, and operations — CEO, CFO, CDO, QA Manager, Research Scientists, and Research Associates. Email your CV to shashisantosh2007@gmail.com.

Stay ahead of DNA damage research

Monthly updates on the POLEX platform, publications, and open roles. No spam.